Meet Our Team ➲



BRITE BIO Leadership Team

Brite Bio is a woman owned small business. Formed in 2012 by Dr. Renee Lea-Currie, our mission is to provide the highest quality human cell systems, reagents and contract services to our research partners; to develop and commercialize innovative research tools, leverage our expertise through research and development and strategic alliances that accelerate discovery.

BriteBio has a well-seasoned team of business and scientific leaders to help build and maintain a quality efficient and lean operation. All team members have years of experience operating in the biotech, University, and Pharmaceutical space as well as experience contract management and compliance.

We welcome the opportunity to discuss your research needs, so please do not hesitate to contact us.

Leadership

Renee Lea-Currie, Brite Bio
Dr. Renee Lea-Currie, PhD,
President & Founder

Brite Bio is a woman owned small business. Our mission is to provide the highest quality human cell systems, reagents and contract services to our research partners; to develop and commercialize innovative research tools, leverage our expertise through research and development and strategic alliances that accelerate discovery.
Director Cell Biology

Experience:

Cell Biology
Nutrition

John Ludlow
Dr. John W. Ludlow, PhD
Chief Scientific Officer

John W. Ludlow, Ph.D, is currently the Chief Scientific Officer of Brite Bio Inc. Prior to joining the company in 2012, he was Senior Director, Process Research and Assay Development at Tengion Inc., a tissue engineering and regenerative medicine company located in Winston-Salem, NC. John has also held the position of Senior Director, Cell Therapy Program, Vesta Therapeutics, Inc., (formerly Incara Pharmaceuticals) here in Research Triangle Park. He has developed and managed research and pre-clinical programs, initiated clinical trial sites, and directed development activities for cell therapy and tissue engineered products. John has also worked closely with regulatory agencies to help ensure approval of the company's products and is an inventor on 3 issued patents in the cell therapy and tissue engineering space. He specializes in laboratory-based research and development of cell and tissue engineered products for regenerative medicine applications. John started his career as a faculty member at the University of Rochester Cancer Center (NY), where he maintained an independently funded research laboratory training graduate students and post-doctoral fellows in the area of tumor suppressor gene expression, protein structure, and function.

Experience:

Tissue Engineering
Product Development

Bill Wilkison, Brite Bio
Bill Wilkison, PhD

Dr. Wilkison joined GlaxoSmithKline in Worldwide Business Development in July 2002 taking on alliance management responsibility for a broad range of strategic alliances between GSK and external partners, including early and late stage drug development and manufacturing, biotechnology platforms and medical device companies. Prior to joining GSK, Dr. Wilkison served in executive positions from 1998 to 2002 at Artecel Sciences and Zen-Bio, as well as being a founder and Board of Director member for both companies. Dr. Wilkison received his Ph.D. in Biochemistry from Duke University Medical Center and his B.S. in Chemistry/Biology from Memphis State University.

Experience:

Jonathan Horowitz, Brite Bio
Dr. Jonathan M Horowitz, PhD

Dr. Horowitz is a molecular biologist focusing on mechanisms of cancer cell development. He has held faculty positions at Brown University, Duke University, and most recently at North Carolina State University, where he serves as Oncology Core Leader in the Center for Comparative Medicine and Translational Research, Cancer Initiative Leader in the Center for Human Health and the Environment, and Assistant Department Head in the Department of Molecular Biomedical Sciences.

Experience:

Kristine Bergstrand, Brite Bio
Dr. Kristine Bergstrand, DVM

Dr. Bergstrand holds a Doctorate in Veterinary Medicine and specializes in small and large animal preclinical models. Recent positions include Talecris Biotherapeutics (currently Grifols) in RTP, NC, where she designed and managed several animal studies, including data acquisition, interpretation, and final reporting. She focuses on IACUC compliant protocol development, design, and execution.

Experience:

Robert Susick, Brite Bio
Dr. Robert Susick, PhD

Dr. Susick is a toxicologist with over 25 years experience in regulatory safety assessment and an expert in non-clinical plan development, study, and program management. He has held positions in small (Sphinx Pharmaceutical Corporation, Durham, NC; Incara Pharmaceuticals, RTP, NC) and large (Eli Lilly and Company, Indianapolis, IN; Park Davis/Warner-Lambert, Ann Arbor, MI) biotechnology and pharmaceutical companies serving as a specialist in nonclinical safety assessment and drug development

Experience: